431809944	431809944	CD	B-NP	O
|	|	NNP	I-NP	O
RH	RH	NNP	I-NP	O
|	|	VBD	B-VP	O
88791704	88791704	CD	B-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
8481228	8481228	CD	B-NP	O
|	|	CC	I-NP	O
10/15/2005	10/15/2005	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	O
pyelonephritis	pyelonephritis	NN	I-NP	O
,	,	,	O	O
urosepsis	urosepsis	NN	B-NP	O
|	|	NNP	I-NP	O
|	|	NNP	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
10/15/2005	10/15/2005	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Discharge	Discharge	NNP	B-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
11/28/2005	11/28/2005	CD	B-NP	O
******	******	SYM	I-NP	O
FINAL	FINAL	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
ORDERS	ORDERS	NNS	I-NP	O
******	******	SYM	O	O
WOODBURY	WOODBURY	NNP	B-NP	O
,	,	,	O	O
CHRISTOPHER	CHRISTOPHER	NNP	B-NP	O
C.	C.	NNP	I-NP	O
963-57-84-4	963-57-84-4	CD	I-NP	O
Own	Own	NNP	I-NP	O
Si	Si	NNP	I-NP	O
A	A	NNP	I-NP	O
Service	Service	NNP	I-NP	O
:	:	:	O	O
MED	MED	NNP	B-NP	O
DISCHARGE	DISCHARGE	NNP	I-NP	O
PATIENT	PATIENT	NNP	I-NP	O
ON	ON	NNP	I-NP	O
:	:	:	O	O
10/25/05	10/25/05	CD	B-NP	O
AT	AT	NN	I-NP	O
01	01	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
PM	PM	NNP	I-NP	O
CONTINGENT	CONTINGENT	NNP	I-NP	O
UPON	UPON	NNP	I-NP	O
Not	Not	NNP	I-NP	O
Applicable	Applicable	NNP	I-NP	O
WILL	WILL	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
ORDER	ORDER	NNP	I-NP	O
BE	BE	NNP	I-NP	O
USED	USED	NNP	I-NP	O
AS	AS	NNP	I-NP	O
THE	THE	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
SUMMARY	SUMMARY	NNP	I-NP	O
:	:	:	O	O
YES	YES	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
TRUSSELL	TRUSSELL	NNP	B-NP	O
,	,	,	O	O
JERE	JERE	NNP	B-NP	O
SCOT	SCOT	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
DISPOSITION	DISPOSITION	NNP	I-NP	O
:	:	:	O	O
Home	Home	NN	B-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-NP	O
services	service	NNS	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
ACETYLSALICYLIC	ACETYLSALICYLIC	NN	B-NP	O
ACID	ACID	NN	I-NP	O
81	81	CD	B-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
QD	QD	NNP	I-NP	O
LISINOPRIL	LISINOPRIL	NNP	I-NP	O
10	10	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
QD	QD	NNP	I-NP	O
Starting	Starting	NNP	I-NP	O
Today	Today	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
9/19	9/19	CD	I-NP	O
-RRB-	-RRB-	HYPH	I-NP	O
HOLD	HOLD	NN	I-NP	B-protein
IF	IF	NN	I-NP	I-protein
:	:	:	O	O
sbp	sbp	NN	B-NP	O
<	<	SYM	O	O
95	95	CD	B-NP	O
Override	Override	NNP	I-NP	O
Notice	Notice	NNP	I-NP	O
:	:	:	O	O
Override	Override	NNP	B-NP	O
added	add	VBD	B-VP	O
on	on	IN	B-PP	O
11/10/05	11/10/05	CD	B-NP	O
by	by	IN	B-PP	O
PRAWL	PRAWL	NN	B-NP	B-protein
,	,	,	O	O
LUCIO	LUCIO	NN	B-NP	O
A.	A.	NN	I-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
KCL	KCL	NNP	B-NP	O
SLOW	SLOW	NNP	I-NP	O
RELEASE	RELEASE	NNP	I-NP	O
PO	PO	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
940668840	940668840	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
LISINOPRIL	LISINOPRIL	NNP	B-NP	O
&	&	CC	I-NP	O
POTASSIUM	POTASSIUM	NNP	I-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
aware	aware	JJ	B-NP	O
Previous	Previous	JJ	I-NP	O
override	override	NN	I-NP	O
information	information	NN	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
11/10/05	11/10/05	CD	B-NP	O
by	by	IN	B-PP	O
MILTZ	MILTZ	NN	B-NP	B-protein
,	,	,	O	O
DOMINIC	DOMINIC	NN	B-NP	O
,	,	,	O	O
M.D.	M.D.	NN	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
LISINOPRIL	LISINOPRIL	NN	B-NP	O
PO	PO	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
113908616	113908616	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Pt	Pt	NN	I-NP	O
.	.	.	O	O

has	have	VBZ	O	O
a	a	DT	B-NP	O
PROBABLE	PROBABLE	NN	I-NP	O
allergy	allergy	NN	I-NP	O
to	to	TO	B-PP	O
ENALAPRIL	ENALAPRIL	NNP	B-NP	O
MALEATE	MALEATE	NNP	I-NP	O
;	;	:	O	O
reactions	reaction	NNS	B-NP	O
are	be	VBP	B-VP	O
HOT	HOT	NNP	B-NP	O
FLASHES	FLASHES	NNP	I-NP	O
,	,	,	O	O
FACIAL	FACIAL	NNP	B-NP	O
FLUSHING	FLUSHING	NNP	I-NP	O
.	.	.	O	O

Reason	Reason	NN	B-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
pt	pt	NN	B-NP	O
has	have	VBZ	B-VP	O
tolerated	tolerate	VBN	I-VP	B-protein
TOPROL	TOPROL	NNP	B-NP	I-protein
XL	XL	NNP	I-NP	I-protein
-LRB-	-LRB-	NNP	I-NP	I-protein
METOPROLOL	METOPROLOL	NNP	I-NP	I-protein
SUCCINATE	SUCCINATE	NNP	I-NP	I-protein
EXTENDED	EXTENDED	NNP	I-NP	I-protein
RELEASE	RELEASE	NNP	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
100	100	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
BID	BID	NNP	I-NP	I-protein
HOLD	HOLD	NN	I-NP	I-protein
IF	IF	NN	I-NP	I-protein
:	:	:	O	O
hr	hr	NN	B-NP	O
<	<	SYM	O	O
55	55	CD	B-NP	O
,	,	,	O	O
sbp	sbp	NN	B-NP	O
<	<	SYM	O	O
95	95	CD	B-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Take	Take	NNP	I-NP	O
consistently	consistently	RB	B-ADVP	O
with	with	IN	B-PP	O
meals	meal	NNS	B-NP	O
or	or	CC	B-PP	O
on	on	IN	B-PP	O
empty	empty	JJ	B-NP	O
stomach	stomach	NN	I-NP	O
.	.	.	O	O

Alert	Alert	NNP	B-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
11/10/05	11/10/05	CD	B-NP	O
by	by	IN	B-PP	O
APODACA	APODACA	NNP	B-NP	O
,	,	,	O	O
RORY	RORY	NNP	B-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
DILTIAZEM	DILTIAZEM	NN	B-NP	O
HCL	HCL	NN	I-NP	O
&	&	CC	I-NP	O
METOPROLOL	METOPROLOL	NNP	I-NP	O
TARTRATE	TARTRATE	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
aware	aware	JJ	B-NP	O
Number	Number	NNP	I-NP	O
of	of	IN	B-PP	O
Doses	Doses	NNP	B-NP	O
Required	Required	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
approximate	approximate	JJ	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
:	:	:	O	O
6	6	CD	B-NP	O
LANTUS	LANTUS	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
INSULIN	INSULIN	NNP	I-NP	O
GLARGINE	GLARGINE	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
19	19	CD	I-NP	O
UNITS	UNITS	NNP	I-NP	O
QAM	QAM	NNP	I-NP	O
SC	SC	NNP	I-NP	O
QAM	QAM	NNP	I-NP	O
19	19	CD	I-NP	O
UNITS	UNITS	NNP	I-NP	O
QAM	QAM	NNP	I-NP	O
Starting	Starting	NNP	I-NP	O
Today	Today	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
8/24	8/24	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Instructions	Instruction	NNPS	I-NP	O
:	:	:	O	O
1/2	1/2	CD	B-NP	O
dose	dose	NN	I-NP	O
if	if	IN	B-SBAR	O
pt	pt	JJ	B-NP	O
npo	npo	NN	I-NP	O
or	or	CC	O	O
decreased	decrease	VBN	B-NP	O
po	po	NN	I-NP	O
's	's	POS	B-NP	O
WARFARIN	WARFARIN	NNP	I-NP	O
SODIUM	SODIUM	NNP	I-NP	O
5	5	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
QPM	QPM	NNP	I-NP	O
Starting	Starting	NNP	I-NP	O
ROUTINE	ROUTINE	NNP	I-NP	O
,	,	,	O	O
20	20	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
Standard	Standard	NNP	I-NP	O
Admin	Admin	NNP	I-NP	O
Time	Time	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
No	No	NNP	I-NP	O
high	high	JJ	I-NP	O
Vitamin-K	Vitamin-K	NN	I-NP	O
containing	contain	VBG	B-VP	O
foods	food	NNS	B-NP	O
Alert	Alert	NNP	B-NP	O
overridden	overridden	JJ	B-ADJP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
11/10/05	11/10/05	CD	B-NP	O
by	by	IN	B-PP	O
:	:	:	O	O
POTENTIALLY	POTENTIALLY	NNP	B-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
ASPIRIN	ASPIRIN	NNP	B-NP	O
&	&	CC	I-NP	O
WARFARIN	WARFARIN	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
ATORVASTATIN	ATORVASTATIN	NNP	B-NP	O
CALCIUM	CALCIUM	NNP	I-NP	O
&	&	CC	I-NP	O
WARFARIN	WARFARIN	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
aware	aware	JJ	B-NP	O
ROSIGLITAZONE	ROSIGLITAZONE	NN	I-NP	O
2	2	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
QD	QD	NN	I-NP	O
FUROSEMIDE	FUROSEMIDE	NN	I-NP	O
20	20	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
BID	BID	NNP	I-NP	O
Starting	Starting	NNP	I-NP	O
Today	Today	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
9/19	9/19	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
PRN	PRN	NNP	I-NP	O
Other	Other	NNP	I-NP	O
:	:	:	O	O
LE	LE	NN	B-NP	O
edema	edema	NN	I-NP	O
Instructions	Instruction	NNS	I-NP	O
:	:	:	O	O
Do	Do	VBP	B-VP	O
not	not	RB	I-VP	O
use	use	VB	I-VP	O
more	more	JJR	B-NP	O
than	than	IN	I-NP	O
1-2	1-2	CD	I-NP	O
days	day	NNS	I-NP	O
per	per	IN	B-PP	O
week	week	NN	B-NP	O
for	for	IN	B-PP	O
potential	potential	JJ	B-NP	O
toxicity	toxicity	NN	I-NP	O
with	with	IN	B-PP	O
digoxin	digoxin	NN	B-NP	O
.	.	.	O	O

SIMVASTATIN	SIMVASTATIN	NN	B-NP	O
10	10	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
QHS	QHS	NNP	I-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Avoid	Avoid	NNP	I-NP	O
grapefruit	grapefruit	NN	I-NP	O
unless	unless	IN	B-SBAR	O
MD	MD	NN	B-NP	B-DNA
instructs	instruct	NNS	I-NP	I-DNA
otherwise	otherwise	RB	B-ADVP	O
.	.	.	O	O

Alert	Alert	NNP	B-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
11/10/05	11/10/05	CD	B-NP	O
by	by	IN	B-PP	O
:	:	:	O	O
POTENTIALLY	POTENTIALLY	NNP	B-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
WARFARIN	WARFARIN	NNP	B-NP	O
&	&	CC	I-NP	O
SIMVASTATIN	SIMVASTATIN	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
already	already	RB	B-ADVP	O
tolerated	tolerate	VBN	B-VP	O
,	,	,	O	O
home	home	NN	B-NP	O
medication	medication	NN	I-NP	O
,	,	,	O	O
aware	aware	JJ	B-NP	O
CEFPODOXIME	CEFPODOXIME	NN	I-NP	O
PROXETIL	PROXETIL	NN	I-NP	O
200	200	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
BID	BID	NN	I-NP	O
X	X	SYM	B-VP	O
16	16	CD	B-NP	O
doses	dose	NNS	I-NP	O
Starting	Start	VBG	B-VP	O
Today	Today	NN	B-NP	O
-LRB-	-LRB-	HYPH	B-NP	O
9/19	9/19	CD	I-NP	O
-RRB-	-RRB-	SYM	I-NP	O
HOLD	HOLD	NN	I-NP	O
IF	IF	NN	I-NP	O
:	:	:	O	O
rash	rash	NN	B-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Give	Give	NNP	I-NP	O
with	with	IN	B-PP	O
meals	meal	NNS	B-NP	O
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	B-ADJP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
11/10/05	11/10/05	CD	B-NP	O
by	by	IN	B-PP	O
:	:	:	O	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
CEFPODOXIME	CEFPODOXIME	NN	B-NP	O
PROXETIL	PROXETIL	NN	I-NP	O
PO	PO	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
626328168	626328168	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Pt	Pt	NN	I-NP	O
.	.	.	O	O

has	have	VBZ	O	O
a	a	DT	B-NP	O
POSSIBLE	POSSIBLE	NN	I-NP	O
allergy	allergy	NN	I-NP	O
to	to	TO	B-PP	O
Penicillins	Penicillins	NNP	B-NP	O
;	;	:	O	O
reaction	reaction	NN	B-NP	O
is	be	VBZ	B-VP	O
RASH	RASH	NN	B-NP	B-protein
.	.	.	O	O

Reason	Reason	NN	B-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
can	can	MD	B-VP	O
not	not	RB	I-VP	O
tolerate	tolerate	VB	I-VP	O
floroquinolones	floroquinolone	NNS	B-NP	O
and	and	CC	O	O
needs	need	VBZ	B-VP	O
gram	gram	NN	B-NP	O
neg	neg	NN	I-NP	O
coverage	coverage	NN	I-NP	O
.	.	.	O	O

has	have	VBZ	B-VP	O
tolerated	tolerate	VBN	I-VP	O
cefalosporins	cefalosporin	NNS	B-NP	O
well	well	RB	B-ADVP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
past	past	NN	I-NP	O
.	.	.	O	O

DIGOXIN	DIGOXIN	NN	B-NP	O
0.125	0.125	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
QOD	QOD	NN	I-NP	O
DIET	DIET	NN	I-NP	O
:	:	:	O	O
House	House	NN	B-NP	O
/	/	SYM	I-NP	O
NAS	NAS	NN	I-NP	B-protein
/	/	SYM	B-VP	O
ADA	ADA	NN	B-NP	O
2000	2000	CD	I-NP	O
cals/day	cals/day	NN	I-NP	O
/	/	SYM	B-NP	O
Low	Low	NN	I-NP	O
saturated	saturate	VBD	B-VP	O
fat	fat	JJ	B-NP	O
low	low	JJ	I-NP	O
cholesterol	cholesterol	NN	I-NP	O
/	/	SYM	B-NP	O
low	low	JJ	I-NP	O
vit	vit	NN	I-NP	O
k	k	NN	I-NP	O
foods	food	NNS	I-NP	O
-LRB-	-LRB-	NNP	B-NP	O
FDI	FDI	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
ACTIVITY	ACTIVITY	NNP	I-NP	O
:	:	:	O	O
Walking	Walk	VBG	B-VP	O
as	as	IN	B-SBAR	O
tolerated	tolerate	VBN	B-NP	O
FOLLOW	FOLLOW	NNP	I-NP	O
UP	UP	NNP	I-NP	O
APPOINTMENT	APPOINTMENT	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
S	S	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
:	:	:	O	O
Dr.	Dr.	NNP	B-NP	O
Maobi	Maobi	NNP	I-NP	O
within	within	IN	B-PP	O
1wk	1wk	CD	B-NP	O
,	,	,	O	O
ALLERGY	ALLERGY	NNP	B-NP	O
:	:	:	O	O
Penicillins	Penicillins	NNP	B-NP	O
,	,	,	O	O
ENALAPRIL	ENALAPRIL	NNP	B-NP	O
MALEATE	MALEATE	NNP	I-NP	O
ADMIT	ADMIT	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
:	:	:	O	O
pyelonephritis	pyelonephritis	NN	B-NP	O
,	,	,	O	O
urosepsis	urosepsis	NN	B-NP	O
PRINCIPAL	PRINCIPAL	NNP	I-NP	O
DISCHARGE	DISCHARGE	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
;	;	:	O	O
Responsible	Responsible	JJ	B-ADJP	O
After	After	IN	B-PP	O
Study	Study	NN	B-NP	O
for	for	IN	B-PP	O
Causing	Cause	VBG	B-VP	O
Admission	Admission	NN	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
pyelonephritis	pyelonephritis	NN	I-NP	O
,	,	,	O	O
urosepsis	urosepsis	NN	B-NP	O
OTHER	OTHER	NN	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
;	;	:	O	O
Conditions	Condition	NNS	B-NP	O
,	,	,	O	O
Infections	Infection	NNS	B-NP	O
,	,	,	O	O
Complications	Complication	NNS	B-NP	O
,	,	,	O	O
affecting	affect	VBG	B-VP	O
Treatment/Stay	Treatment/Stay	NNP	B-NP	O
AFIB	AFIB	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
atrial	atrial	JJ	I-NP	O
fibrillation	fibrillation	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
PYELONEPHRITIS	PYELONEPHRITIS	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
pyelonephritis	pyelonephritis	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
DM	DM	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
diabetes	diabetes	NN	I-NP	O
mellitus	mellitus	NN	I-NP	O
type	type	NN	I-NP	O
2	2	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
HTN	HTN	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
hypertension	hypertension	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
HYPERLIPID	HYPERLIPID	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
hyperlipidemia	hyperlipidemia	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
OPERATIONS	OPERATIONS	NNS	I-NP	O
AND	AND	CC	I-NP	O
PROCEDURES	PROCEDURES	NNS	I-NP	O
:	:	:	O	O
none	none	NN	B-NP	O
OTHER	OTHER	NN	I-NP	O
TREATMENTS/PROCEDURES	TREATMENTS/PROCEDURES	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
NOT	NOT	NNP	I-NP	O
IN	IN	NNP	I-NP	O
O.R.	O.R.	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
TTE	TTE	NNP	I-NP	O
,	,	,	O	O
Adenosine-MIBI	Adenosine-MIBI	NNP	B-NP	O
,	,	,	O	O
PE	PE	NNP	B-NP	O
protocol	protocol	NN	I-NP	O
CT	CT	NNP	I-NP	O
BRIEF	BRIEF	NNP	I-NP	O
RESUME	RESUME	NNP	I-NP	O
OF	OF	IN	B-PP	O
HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
77	77	CD	B-NP	O
year	year	NN	I-NP	O
old	old	JJ	I-NP	O
woman	woman	NN	I-NP	O
admitted	admit	VBN	B-VP	O
with	with	IN	B-PP	O
complaint	complaint	NN	B-NP	O
of	of	IN	B-PP	O
urinary	urinary	JJ	B-NP	O
frequency	frequency	NN	I-NP	O
and	and	CC	I-NP	O
AMS	AMS	NN	I-NP	B-protein
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
positive	positive	JJ	B-NP	O
blood	blood	NN	I-NP	O
and	and	CC	I-NP	O
urine	urine	NN	I-NP	O
cultures	culture	NNS	I-NP	O
for	for	IN	B-PP	O
Klebsiella	Klebsiella	NN	B-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
AFIB	AFIB	NN	I-NP	B-protein
became	become	VBD	B-VP	O
tachy	tachy	JJ	B-ADJP	O
to	to	TO	B-PP	O
140	140	CD	B-NP	O
's	's	POS	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
an	an	DT	B-NP	O
elevated	elevated	JJ	I-NP	O
troponin	troponin	NN	I-NP	O
to	to	TO	B-PP	O
1.69	1.69	CD	B-NP	O
which	which	WDT	B-NP	O
rose	rise	VBD	B-VP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
max	max	NN	I-NP	O
of	of	IN	B-PP	O
2.41	2.41	CD	B-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
ekg	ekg	NN	I-NP	O
changes	change	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
rate	rate	NN	B-NP	O
controlled	controlled	JJ	I-NP	O
and	and	CC	O	O
started	start	VBN	B-VP	O
on	on	IN	B-PP	O
Levofloxacin	Levofloxacin	NN	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
mental	mental	JJ	I-NP	O
status	status	NN	I-NP	O
improved	improve	VBN	B-VP	O
and	and	CC	O	O
fever	fever	NN	B-NP	O
resolved	resolve	VBN	B-VP	O
.	.	.	O	O

She	She	PRP	B-NP	O
remained	remain	VBD	B-VP	O
tachycardic	tachycardic	JJ	B-NP	O
and	and	CC	I-NP	O
nodal	nodal	JJ	I-NP	O
block	block	NN	I-NP	O
was	be	VBD	B-VP	O
supressing	supresse	VBG	I-VP	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
digoxin	digoxin	NN	B-NP	O
with	with	IN	B-PP	O
excellent	excellent	JJ	B-NP	O
response	response	NN	I-NP	O
.	.	.	O	O

HR	HR	NN	B-NP	O
stayed	stay	VBD	B-VP	O
in	in	IN	B-PP	O
70-80	70-80	CD	B-NP	O
's	's	POS	B-NP	O
and	and	CC	O	O
up	up	IN	B-PP	O
to	to	TO	B-PP	O
100	100	CD	B-NP	O
's	's	POS	B-NP	O
with	with	IN	B-PP	O
exersion	exersion	NN	B-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
cardiac	cardiac	JJ	I-NP	O
workup	workup	NN	I-NP	O
included	include	VBD	B-VP	O
an	an	DT	B-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
with	with	IN	B-PP	O
RV	RV	NN	B-NP	O
dialation	dialation	NN	I-NP	O
and	and	CC	O	O
wall	wall	NN	B-NP	O
akinesis	akinesis	NN	I-NP	O
with	with	IN	B-PP	O
apical	apical	JJ	B-NP	O
sparing	sparing	NN	I-NP	O
,	,	,	O	O
a	a	DT	B-NP	O
new	new	JJ	I-NP	O
finding	finding	NN	I-NP	O
since	since	IN	B-PP	O
last	last	JJ	B-NP	O
echo	echo	NN	I-NP	O
in	in	IN	B-PP	O
'	'	''	O	O
03	03	CD	B-NP	O
.	.	.	O	O

Right	Right	RB	B-ADVP	O
sided	side	VBD	B-VP	O
EKG	EKG	NN	B-NP	O
neg	neg	NN	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
PE	PE	NN	I-NP	O
was	be	VBD	B-VP	O
then	then	RB	I-VP	O
ruled	rule	VBN	I-VP	O
out	out	RP	B-PRT	O
with	with	IN	B-PP	O
PE	PE	NN	B-NP	O
protocol	protocol	NN	I-NP	O
CT.	CT.	NNP	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
following	follow	VBG	I-NP	O
day	day	NN	I-NP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
adenosine	adenosine	NN	I-NP	B-DNA
MIBI	MIBI	NN	I-NP	I-DNA
that	that	WDT	B-NP	O
showed	show	VBD	B-VP	O
no	no	DT	B-NP	O
perfusion	perfusion	NN	I-NP	O
defects	defect	NNS	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
was	be	VBD	B-VP	O
increasing	increase	VBG	I-VP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
levofloxacin	levofloxacin	NN	I-NP	O
effect	effect	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
switched	switch	VBN	I-VP	O
to	to	TO	B-PP	O
ceftriaxone	ceftriaxone	NN	B-NP	O
consistant	consistant	JJ	B-ADJP	O
with	with	IN	B-PP	O
blood	blood	NN	B-NP	O
culture	culture	NN	I-NP	O
succeptabilities	succeptability	NNS	I-NP	O
.	.	.	O	O

Follow	Follow	VB	B-VP	O
up	up	RP	B-PRT	O
blood	blood	NN	B-NP	O
cultures	culture	NNS	I-NP	O
on	on	IN	B-PP	O
3/11	3/11	CD	B-NP	O
then	then	RB	B-ADVP	O
demostrated	demostrate	VBD	B-VP	O
gram	gram	NN	B-NP	O
positive	positive	JJ	I-NP	O
cocci	coccus	NNS	I-NP	O
in	in	IN	B-PP	O
clusters	cluster	NNS	B-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
2	2	CD	B-NP	O
doses	dose	NNS	I-NP	O
of	of	IN	B-PP	O
vancomycin	vancomycin	NN	B-NP	O
to	to	TO	B-VP	O
cover	cover	VB	I-VP	O
potential	potential	JJ	B-NP	O
staph	staph	NN	I-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

Cultures	Culture	NNS	B-NP	O
were	be	VBD	B-VP	O
found	find	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
skin	skin	NN	B-NP	O
flora	flora	NN	I-NP	O
and	and	CC	O	O
patient	patient	NN	B-NP	O
asymptomatic	asymptomatic	JJ	I-NP	O
and	and	CC	I-NP	O
antibiotics	antibiotic	NNS	I-NP	O
d/c	d/c	NN	I-NP	O
'd	'd	NN	I-NP	O
.	.	.	O	O

Repeat	Repeat	NN	B-NP	O
cultures	culture	NNS	I-NP	O
were	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
in	in	IN	B-PP	O
good	good	JJ	B-NP	O
condition	condition	NN	I-NP	O
and	and	CC	O	O
will	will	MD	B-VP	O
return	return	VB	I-VP	O
to	to	TO	B-PP	O
PCP	PCP	NN	B-NP	B-DNA
for	for	IN	B-PP	O
close	close	JJ	B-ADJP	O
follow	follow	VB	B-VP	O
up	up	IN	B-PRT	O
.	.	.	O	O

ADDITIONAL	ADDITIONAL	JJ	B-NP	O
COMMENTS	COMMENTS	NNS	I-NP	O
:	:	:	O	O
Call	Call	VB	B-VP	O
PCP	PCP	NN	B-NP	B-protein
with	with	IN	B-PP	O
any	any	DT	B-NP	O
changes	change	NNS	I-NP	O
in	in	IN	B-PP	O
urinary	urinary	JJ	B-NP	O
symptoms	symptom	NNS	I-NP	O
,	,	,	O	O
or	or	CC	O	O
fever	fever	NN	B-NP	O
>	>	SYM	B-NP	O
101.0	101.0	CD	B-NP	O
.	.	.	O	O

Return	Return	NN	B-NP	O
to	to	TO	B-PP	O
ER	ER	NN	B-NP	B-protein
if	if	IN	B-SBAR	O
any	any	DT	B-NP	O
changes	change	NNS	I-NP	O
in	in	IN	B-PP	O
mental	mental	JJ	B-NP	O
status	status	NN	I-NP	O
,	,	,	O	O
chest	chest	NN	B-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
SOB	SOB	NN	B-NP	B-protein
,	,	,	O	O
or	or	CC	O	O
syncope	syncope	NN	B-NP	O
.	.	.	O	O

Complete	Complete	VB	B-VP	O
the	the	DT	B-NP	O
full	full	JJ	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
antibiotics	antibiotic	NNS	B-NP	O
which	which	WDT	B-NP	O
cover	cover	VBP	B-VP	O
the	the	DT	B-NP	O
next	next	JJ	I-NP	O
8days	8day	NNS	I-NP	O
.	.	.	O	O

F/U	F/U	NN	B-NP	O
with	with	IN	B-PP	O
PCP	PCP	NN	B-NP	B-protein
within	within	IN	B-PP	O
the	the	DT	B-NP	O
next	next	JJ	I-NP	O
week	week	NN	I-NP	O
with	with	IN	B-PP	O
INR	INR	NN	B-NP	B-protein
and	and	CC	I-NP	O
digoxin	digoxin	NN	I-NP	O
levels	level	NNS	I-NP	O
.	.	.	O	O

Do	Do	VBP	B-VP	O
not	not	RB	I-VP	O
use	use	VB	I-VP	O
lasix	lasix	NN	B-NP	O
unless	unless	IN	B-SBAR	O
necessary	necessary	JJ	B-NP	O
and	and	CC	I-NP	O
contact	contact	NN	I-NP	O
PCP	PCP	NN	I-NP	O
if	if	IN	B-SBAR	O
using	use	VBG	B-VP	O
more	more	JJR	B-NP	O
than	than	IN	I-NP	O
1-2	1-2	CD	I-NP	O
times	time	NNS	I-NP	O
per	per	IN	B-PP	O
week	week	NN	B-NP	O
due	due	JJ	B-PP	O
to	to	TO	B-PP	O
possible	possible	JJ	B-NP	O
toxicity	toxicity	NN	I-NP	O
with	with	IN	B-PP	O
digoxin	digoxin	NN	B-NP	O
use	use	NN	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
CONDITION	CONDITION	NN	I-NP	O
:	:	:	O	O
Stable	Stable	JJ	B-NP	O
TO	TO	NN	I-NP	O
DO/PLAN	DO/PLAN	NN	I-NP	O
:	:	:	O	O
VNA	VNA	NN	B-NP	O
instructions	instruction	NNS	I-NP	O
:	:	:	O	O
Please	Please	NN	B-NP	B-protein
do	do	VBP	B-VP	O
vital	vital	JJ	B-NP	O
signs	sign	NNS	I-NP	O
checks	check	NNS	I-NP	O
.	.	.	O	O

Patient	Patient	NN	B-NP	O
needs	need	VBZ	B-VP	O
a	a	DT	B-NP	O
digoxin	digoxin	NN	I-NP	O
level	level	NN	I-NP	O
and	and	CC	I-NP	O
INR	INR	NN	I-NP	B-protein
checked	check	VBD	B-VP	O
weekly	weekly	RB	B-ADVP	O
,	,	,	O	O
and	and	CC	O	O
the	the	DT	B-NP	O
first	first	JJ	I-NP	O
set	set	NN	I-NP	O
of	of	IN	B-PP	O
labs	lab	NNS	B-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
drawn	draw	VBN	I-VP	O
1-2	1-2	CD	B-NP	O
days	day	NNS	I-NP	O
after	after	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

PCP	PCP	NN	B-NP	O
will	will	MD	B-VP	O
follow-up	follow-up	VB	I-VP	O
labs	lab	NNS	B-NP	O
.	.	.	O	O

Guiac	Guiac	NN	B-NP	O
+	+	SYM	O	O
x	x	SYM	B-NP	O
1	1	CD	I-NP	O
needs	need	NNS	I-NP	O
f/u	f/u	NN	I-NP	O
.	.	.	O	O

TO	TO	TO	B-PP	O
THE	THE	DT	B-NP	O
PATIENT	PATIENT	NN	I-NP	O
:	:	:	O	O
We	We	PRP	B-NP	O
have	have	VBP	B-VP	O
altered	alter	VBN	I-VP	O
cardiac	cardiac	JJ	B-NP	O
medications	medication	NNS	I-NP	O
for	for	IN	B-PP	O
better	good	JJR	B-NP	O
rate	rate	NN	I-NP	O
control	control	NN	I-NP	O
.	.	.	O	O

We	We	PRP	B-NP	O
have	have	VBP	B-VP	O
cancelled	cancel	VBN	I-VP	O
the	the	DT	B-NP	O
coreg	coreg	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
carvedelol	carvedelol	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
and	and	CC	O	O
Norvasc	Norvasc	NN	B-NP	O
-LRB-	-LRB-	NN	I-NP	O
amilodipine	amilodipine	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
and	and	CC	O	O
replaced	replace	VBD	B-VP	O
them	them	PRP	B-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
medication	medication	NN	I-NP	O
,	,	,	O	O
Toprol	Toprol	NNP	B-NP	O
XL	XL	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
Metoprolol	Metoprolol	NNP	I-NP	O
XL	XL	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
to	to	TO	B-VP	O
better	well	RBR	I-VP	O
control	control	VB	I-VP	O
the	the	DT	B-NP	O
rate	rate	NN	I-NP	O
of	of	IN	B-PP	O
your	your	PRP$	B-NP	O
atrial	atrial	JJ	I-NP	O
fibrillation	fibrillation	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
digoxin	digoxin	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
added	add	VBN	I-VP	O
for	for	IN	B-PP	O
heart	heart	NN	B-NP	O
rate	rate	NN	I-NP	O
control	control	NN	I-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
dictated	dictated	JJ	I-NP	O
summary	summary	NN	I-NP	O
ENTERED	ENTERED	NNP	I-NP	O
BY	BY	NNP	I-NP	O
:	:	:	O	O
FASSNACHT	FASSNACHT	NNP	B-NP	O
,	,	,	O	O
LUCAS	LUCAS	NNP	B-NP	B-protein
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
JC43	JC43	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
10/25/05	10/25/05	CD	I-NP	O
@	@	SYM	B-NP	O
01	01	CD	I-NP	O
******	******	SYM	I-NP	O
END	END	NN	I-NP	O
OF	OF	IN	B-PP	O
DISCHARGE	DISCHARGE	NN	B-NP	O
ORDERS	ORDERS	NNS	I-NP	O
******	******	SYM	B-NP	O

